Hung Nguyen Thanh
Department of Dengue Hemorrhagic Fever, Children’s Hospital No. 1, Ho Chi Minh City, Viet Nam.
Paediatr Int Child Health. 2012 May;32 Suppl 1(s1):39-42. doi: 10.1179/2046904712Z.00000000051.
Dengue is a serious public health problem worldwide. Dengue shock syndrome (DSS), the severe form of dengue fever, can cause death within 12-24 hours if appropriate treatment is not promptly administered. For patients with DSS and the 30% of non-shocked dengue patients who require intravenous fluid therapy, a range of solutions is available for plasma volume support. Crystalloid solutions, such as normal 0·9% saline or Ringer's lactate, are the ones most commonly used. In severe cases, colloid solutions may be administered for their greater osmotic effect, although they carry a greater risk of adverse events. This paper summarises the key clinical data, comparing fluid regimens in children with severe dengue, and concludes that the majority of patients with DSS can be treated successfully with isotonic crystalloid solutions. If a colloid is thought necessary, a medium-molecular-weight preparation that combines good initial plasma volume support with good intravascular persistence and an acceptable side-effect profile is optimal. Further research should aim to determine whether there are benefits to early treatment with colloids, and which colloid solution is most effective for resuscitation of DSS patients.
登革热是全球严重的公共卫生问题。登革热休克综合征(DSS)是登革热的严重形式,如果不及时给予适当治疗,可在12 - 24小时内导致死亡。对于患有DSS以及30%需要静脉补液治疗的非休克型登革热患者,有一系列溶液可用于支持血浆容量。晶体溶液,如0.9%的生理盐水或乳酸林格氏液,是最常用的。在严重病例中,胶体溶液因其更大的渗透作用可能会被使用,尽管它们带来不良事件的风险更高。本文总结了关键临床数据,比较了重症登革热患儿的补液方案,并得出结论:大多数DSS患者可用等渗晶体溶液成功治疗。如果认为有必要使用胶体,一种结合了良好的初始血浆容量支持、良好的血管内持久性和可接受的副作用的中分子量制剂是最佳选择。进一步的研究应旨在确定早期使用胶体是否有益,以及哪种胶体溶液对DSS患者的复苏最有效。